The Top Ten Biotech Stocks Right Now

Why it ranks first: Ultragenyx is the only company on the current page with two separate FDA decisions inside the active review window. DTX401 targets glycogen storage disease type Ia, while UX111 targets Sanfilippo syndrome type A. The programs address different diseases, use different clinical packages and represent two distinct regulatory opportunities. That does not eliminate risk, but it prevents the entire current thesis from resting on one coin flip.

The FDA accepted the DTX401 BLA with Priority Review and assigned an August 23 action date. Ultragenyx has also said that the agency did not anticipate an Advisory Committee at the time of acceptance. For UX111, the FDA accepted the resubmission and assigned a September 19 action date. The package includes long-term follow-up extending as far as eight years for some participants, an important consideration for a progressive pediatric neurodegenerative disease.

What matters most before the dates: any FDA communication concerning inspections, manufacturing readiness, labeling, Risk Evaluation and Mitigation Strategy requirements, or post-approval commitments. In rare-disease gene therapy, an apparently positive efficacy package can still be delayed by production or comparability questions.

Merlintrader view: $RARE offers the best balance of catalyst density, corporate quality and survivability. It may not deliver the most extreme percentage move in the group, but it has the most complete current setup.

The central catalyst: Pharvaris expects topline results from CHAPTER-3 during the third quarter of 2026. The pivotal study evaluates once-daily extended-release deucrictibant for prophylactic treatment of hereditary angioedema. Approximately 81 participants were randomized 2:1 to active treatment or placebo for 24 weeks.

This is one of the cleaner clinical setups on the list because the molecule is not entering the pivotal stage without supporting evidence. Deucrictibant has generated data in both acute and prophylactic settings, and the same oral bradykinin B2 receptor antagonism underpins the broader program. The immediate-release formulation also reached a major regulatory milestone when its U.S. NDA was accepted in July 2026, although its PDUFA date falls in April 2027 and therefore sits outside the current ranking’s active review window.

The data details that matter: annualized attack rate, proportion of attack-free patients, consistency across subgroups, rescue-medication use, treatment discontinuations and any signal that efficacy weakens over time. A headline beat is important, but competitive positioning will depend on the entire profile.

Merlintrader view: $PHVS is the best pure pivotal-readout setup in the ranking. It still carries normal Phase 3 risk, but the combination of prior validation, a defined market and adequate capital gives the event a more balanced structure than many binary biotech readouts.

The central setup: EyePoint is approaching topline results from LUGANO, followed shortly afterward by the identical LUCIA study. Together, the two Phase 3 trials enrolled more than 900 patients and evaluate DURAVYU, a sustained-delivery vorolanib intravitreal insert, against on-label aflibercept in wet age-related macular degeneration.

The primary objective is non-inferiority in best-corrected visual acuity at weeks 52 and 56. The strategic attraction is not simply maintaining vision: DURAVYU is designed for redosing every six months, so the commercial thesis also depends on sharply reducing the injection burden that limits real-world anti-VEGF care.

The details that matter: the exact non-inferiority result, mean change in vision, percentage of supplement-free eyes, reduction in injection burden, anatomical control, ocular adverse events and consistency between LUGANO and LUCIA. A positive first study followed by confirmation in the second would be much stronger than a single isolated win.

Merlintrader view: $EYPT belongs near the top because it offers two genuine pivotal events, a large addressable market and sufficient capital to reach the readouts. This is a major clinical test, not an administrative filing milestone.

Tenax expects to report topline data in August from LEVEL, a registrational Phase 3 trial evaluating oral levosimendan, TNX-103, in pulmonary hypertension associated with heart failure with preserved ejection fraction. More than 230 patients were randomized, and the results are scheduled for a late-breaking clinical-science presentation at the European Society of Cardiology Congress on August 29.

This is a strong catalyst because PH-HFpEF is a large and difficult disease setting with no therapy specifically approved for the pulmonary-hypertension component. The primary endpoint is change in six-minute walk distance, a clinically understandable functional measure with direct relevance to symptoms and daily activity.

What to watch in August: placebo-adjusted change in six-minute walk distance, responder analyses, consistency across prespecified subgroups, safety, discontinuations, secondary endpoints and the degree to which the ESC presentation expands beyond the initial topline release.

Merlintrader view: $TENX is one of the strongest overlooked catalysts in the current window. It combines a true Phase 3 value inflection, a defined August readout and enough liquidity to avoid making an immediate financing the only post-data narrative.

Capricor has one of the most compressed and potentially dramatic regulatory paths in the current ranking. The FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee is scheduled to discuss deramiocel on July 29, followed by the August 22 PDUFA date.

The application is supported by HOPE-3, a 106-patient randomized, double-blind, placebo-controlled study. Capricor reported that the trial met its primary endpoint on the Performance of the Upper Limb scale and its key cardiac endpoint measuring left-ventricular ejection fraction, together with the prespecified Type I error-controlled secondary endpoints. These results gave the program a stronger clinical foundation after the FDA issued a Complete Response Letter in 2025.

Merlintrader view: $CAPR may be one of the most powerful event trades in the period, but it should not be confused with a low-risk setup. The briefing documents, panel discussion and vote are likely to matter at least as much as the final FDA date.

MannKind offers a different profile from the classic development-stage biotech. The July 26 FDA decision concerns the FUROSCIX ReadyFlow Autoinjector, designed to administer an intravenous-equivalent dose of furosemide in under ten seconds for adults with edema associated with congestive heart failure or chronic kidney disease.

The second catalyst is more scientifically exploratory but potentially more important over the long term: topline results from INFLO-1 are expected in the third quarter. The study evaluates MNKD-201, an inhaled formulation of nintedanib, in idiopathic pulmonary fibrosis. A successful inhaled approach could support the idea of delivering high pulmonary exposure while attempting to reduce systemic tolerability burden.

What to watch after a positive FDA decision: launch timing, payer coverage, conversion of existing FUROSCIX users, physician training, inventory build and whether the autoinjector materially expands the addressable population. For INFLO-1, the key issues will be pulmonary exposure, tolerability, treatment discontinuations and any early efficacy signal.

Merlintrader view: $MNKD offers one of the more balanced profiles because the company can survive a single disappointing event. It may not be the largest run-up candidate, but it combines an exact regulatory date with a second clinical readout and an established revenue base.

Replimune has the tightest AdCom-to-decision interval in the entire calendar. The FDA committee meets on July 30 to discuss RP1, also known as vusolimogene oderparepvec, in combination with nivolumab for advanced melanoma that has progressed after anti-PD-1 therapy. The FDA goal date follows only three days later on August 2.

The compressed timetable means the market is likely to treat the briefing documents and panel discussion as the true regulatory event. The BLA resubmission was accepted as a Class 1 response, but the history of the program makes the outcome unusually sensitive to questions about evidence quality, response durability and the appropriateness of accelerated approval.

What to watch in the FDA materials: the agency’s framing of the confirmatory trial, adequacy of the proposed population, response-assessment methodology, durability, safety, manufacturing readiness and whether the panel question explicitly tests the accelerated-approval standard.

Merlintrader view: $REPL is one of the highest-volatility candidates in the list. It may produce a major repricing, but the setup contains regulatory, evidence and financing risks that all converge within the same week.

Telix’s September 11 catalyst concerns Pixclara, a PET imaging agent intended to help evaluate recurrent or progressive glioma and distinguish active disease from treatment-related changes. The FDA accepted the NDA and granted a review path supported by Orphan Drug and Fast Track designations.

The medical need is clear: post-treatment brain imaging can be difficult to interpret, and clinicians may struggle to separate true tumor progression from pseudoprogression or radiation-related changes. A more informative imaging tool could improve treatment decisions, patient selection and clinical-trial assessment.

What matters after approval: final label breadth, reimbursement, U.S. launch timing, production capacity, distribution reliability and evidence that Pixclara changes clinical decision-making. Radiopharmaceutical products require more operational infrastructure than conventional tablets, and execution remains critical even after regulatory success.

Merlintrader view: $TLX is included because it offers a cleaner corporate-risk profile than most catalyst trades. The likely percentage reaction may be smaller, but the event sits inside a durable radiopharma growth platform rather than a single-asset survival story.

Cingulate received a Complete Response Letter on June 2 for CTx-1301, its once-daily dexmethylphenidate candidate for attention-deficit/hyperactivity disorder. The reason $CING belongs in the current Top Ten is not that a new PDUFA date has already been assigned—it has not—but that the FDA’s stated objections were focused on specific chemistry, manufacturing and controls requests, with no current concerns identified regarding clinical safety or efficacy.

That distinction creates a classic regulatory-repair setup. The clinical package has not been rejected on efficacy, and management says it is completing the CMC work with its manufacturing partner and expects a prompt submission of the requested information. The equity can therefore react materially to evidence that the manufacturing issues have been resolved, the application has been resubmitted and the FDA has classified the review.

The next real catalysts: completion of the requested CMC work, formal resubmission, FDA acceptance of the response, classification as a Class 1 or Class 2 resubmission, assignment of a new action date and any disclosure about the contract manufacturer or inspection status. Until those occur, the timing must be described as unconfirmed.

Merlintrader view: $CING earns a place in the current ranking because the market is waiting for resolution of a defined FDA deficiency that did not currently challenge the product’s clinical efficacy or safety. The opportunity is meaningful, but the timing remains less predictable than a confirmed PDUFA or scheduled Phase 3 readout.

Outlook Therapeutics has one of the most immediately consequential decisions on the current page. The July 29 PDUFA date concerns ONS-5010, branded LYTENAVA in authorized European markets, as an ophthalmic formulation of bevacizumab for wet age-related macular degeneration.

The program has traveled through an unusually difficult U.S. regulatory history, including multiple Complete Response Letters. A formal dispute-resolution process later produced a favorable conclusion on the substantial-evidence-of-effectiveness question, allowing the company to resubmit the BLA. That procedural win was important, but it does not remove every remaining FDA risk.

What matters beyond the headline: final label, any manufacturing or inspection language, launch timing, distribution agreements, reimbursement, near-term financing terms and the number of additional shares or warrants that could enter the market.

Merlintrader view: $OTLK may deliver one of the largest positive or negative reactions in the calendar, but it is the clearest example of why “largest catalyst” and “best company” are not interchangeable.